112 - Why GLP-1–Only Weight Loss Programs Are Risky in 2026 (And What to Do Instead)

GLP-1 medications have transformed medical weight loss — but in 2026, medication-only models are becoming financially fragile and clinically risky. In this episode of Bariatric Business Accelerator, Karol Clark breaks down why many practices are feeling busier than ever… yet more stretched, reactive, and less profitable. If your program relies heavily on prescribing and refilling GLP-1 medications, this conversation is essential.

🎯 In this episode, you’ll learn: • Why GLP-1 demand is increasing while margins are quietly shrinking • The real impact of high GLP-1 discontinuation rates on retention and revenue • How medication-only weight loss programs create burnout for teams • Why patients want clarity, continuity, and confidence — not just prescriptions • How membership-style care models stabilize revenue and staffing • What an outcomes-driven infrastructure looks like in modern weight loss practices • How to build a “beyond the medication” patient pathway for plateaus, maintenance, and long-term success • Why the most resilient programs in 2026 protect margins through systems, retention, and smarter support — not volume alone GLP-1 medications are here to stay. But the practices that thrive in 2026 and beyond will be those that move beyond transactional visits and build sustainable, system-driven programs that support patients whether they’re on medication or not. If you’re a: • Bariatric surgeon • Medical weight loss provider • Obesity medicine clinician • Lifestyle medicine practitioner • Practice owner or administrator — this episode will help you future-proof your program.

👉 Subscribe for weekly insights on building profitable, patient-centered weight loss practices

👉 Explore free resources at WeightLossPracticeBuilder.com

👉 Reach out directly: [email protected]